Is DHEA-S a reliable marker of adrenal androgen output that declines with age?

Based on the comprehensive clinical evidence, the claim is fully supported. Dehydroepiandrosterone sulfate (DHEA-S) is a reliable, stable biomarker of adrenal androgen output that declines predictably with age, and lower levels serve as a clear physiological indicator of reduced adrenal androgen reserve.

Clinical evidence and diagnostic utility

• Stable Biomarker of Adrenal Output: Unlike other adrenal steroids that fluctuate dramatically due to pulsatile secretion or diurnal rhythms, DHEA-S has a long biological half-life of 10 to 20 hours. This stability in human serum is due to its high water solubility and strong binding to albumin, preventing rapid renal clearance. It represents a highly stable, integrated measure of adrenal androgen production.
• Predictable Age-Dependent Decline: DHEA-S levels peak in late adolescence and young adulthood (ages 15–30) and experience a steady, progressive decline of approximately 10% to 15% per decade. By age 70 to 80, circulating concentrations typically drop to only 10% to 20% of peak young-adult values, a physiological phenomenon known as adrenopause. For a 61-year-old male, levels will naturally be significantly lower than in early adulthood, requiring interpretation against strict age- and sex-adjusted reference ranges.
• Indication of Reduced Adrenal Reserve: Because DHEA-S is synthesized almost exclusively in the adrenal cortex, low circulating levels directly reflect a diminished adrenal androgen reserve. In clinical practice, lower-than-expected age-adjusted DHEA-S can also be an adjunctive indicator of overall hypothalamic-pituitary-adrenal (HPA) axis suppression or chronic ACTH deficiency, often seen in patients with long-term glucocorticoid use or pituitary disorders.

Mechanistic explanations

• Zona Reticularis Involution: The primary biological mechanism driving the age-related decline of DHEA-S is the functional and structural involution of the adrenal zona reticularis—the specific anatomical layer of the adrenal cortex responsible for DHEA-S synthesis.
• Enzymatic Downregulation: With age, there is a progressive decrease in the expression and activity of key steroidogenic enzymes within the zona reticularis, specifically 17,20-lyase (part of the cytochrome P450c17 complex) and sulfotransferase 2A1 (SULT2A1), which directly converts DHEA to its sulfated form (DHEA-S).

Clinical limitations and considerations

• Not a Standalone Diagnostic: While low DHEA-S is a strong marker of reduced adrenal androgen reserve, major clinical guidelines (such as those from the Endocrine Society) do not support using it as a standalone diagnostic tool for adrenal insufficiency. Definitive diagnosis still requires cortisol-based testing, such as a cosyntropin (ACTH) stimulation test.
• Confounding Factors: DHEA-S levels can be transiently or chronically suppressed by systemic acute illness, metabolic syndrome, obesity, and medications—especially exogenous glucocorticoids or opioid therapies.

Bottom line

For a 61-year-old male, DHEA-S is a highly reliable marker of adrenal androgen output. While a lower level physiologically indicates a reduced adrenal androgen reserve, it must be evaluated using age-specific reference ranges and interpreted as an adjunctive marker alongside gold-standard cortisol testing if adrenal insufficiency is suspected.